Nxera Pharma Co., Ltd. (SOLTF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Nxera Pharma Co., Ltd. (SOLTF) Healthcare & Pipeline Overview

Nxera Pharma Co., Ltd., a biopharmaceutical company based in Japan, develops and markets treatments for respiratory diseases, CNS disorders, and metabolic diseases. With a global presence and strategic collaborations, Nxera focuses on advancing its pipeline of novel therapeutics, while currently operating with negative profitability and OTC market trading.

What Is the Investment Thesis for SOLTF?

Nxera Pharma presents a high-risk, high-reward investment opportunity. The company's diverse pipeline and strategic collaborations offer potential for significant revenue growth if key drug candidates are approved and successfully commercialized. However, the company's current negative profit margin of -42.3% and trading on the OTC market indicate substantial financial and liquidity risks. Upcoming clinical trial results for drugs like Daridorexant (insomnia) and HTL0048149 (schizophrenia) could serve as major catalysts. The company's ability to navigate the regulatory landscape and secure partnerships will be critical to its long-term success. Investors should carefully weigh the potential upside against the inherent risks associated with investing in a development-stage biopharmaceutical company with limited profitability.

Based on FMP financials and quantitative analysis

SOLTF Key Highlights

Market capitalization of $460M, reflecting its current valuation in the biotechnology sector.

• Negative P/E ratio of -6.60, indicating that the company is currently not profitable.
• Gross margin of 72.3%, suggesting strong pricing power for its existing products.
• Profit margin of -42.3%, highlighting the company's ongoing investments in research and development.
• Beta of -0.00, indicating a low correlation with the overall market, which may offer some downside protection during market volatility.

Who Are SOLTF's Competitors?

SOLTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SOLTF's Key Strengths?

Diverse product portfolio targeting multiple therapeutic areas.

• Strategic collaborations with major pharmaceutical companies.
• Experienced management team with expertise in drug development.
• Strong gross margin indicating pricing power.

What Are SOLTF's Weaknesses?

Negative profit margin indicating ongoing losses.

• Reliance on successful development and commercialization of pipeline assets.
• Limited financial resources compared to larger pharmaceutical companies.
• Trading on the OTC market, indicating higher risk and lower liquidity.

What Could Drive SOLTF Stock Higher?

Clinical trial results for HTL0048149 for schizophrenia disorders.

• Clinical trial results for Daridorexant for the treatment of insomnia.
• Potential for new strategic collaborations with pharmaceutical companies.
• Regulatory approvals for pipeline assets in key markets.
• Expansion into new geographic markets.

What Are the Key Risks for SOLTF?

Financial-distress signal — its Altman Z-Score of 0.94 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-12.2%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Failure to obtain regulatory approvals for pipeline assets.
• Competition from larger pharmaceutical companies with greater resources.
• Patent expirations and generic competition.
• Negative profit margin and reliance on external funding.
• Trading on the OTC market, indicating higher risk and lower liquidity.

What Are the Growth Opportunities for SOLTF?

• Expansion into New Therapeutic Areas: Nxera Pharma has the opportunity to expand its focus beyond its current core areas of respiratory and CNS disorders. The company's pipeline includes drug candidates targeting metabolic diseases, immuno-oncology, and inflammatory bowel disease. Successful development and commercialization of these assets could significantly broaden Nxera's market reach and revenue streams. The global market for metabolic disease treatments is projected to reach $200 billion by 2028, presenting a substantial growth opportunity.
• Strategic Partnerships and Acquisitions: Nxera Pharma can leverage its existing collaborations with major pharmaceutical companies to pursue further partnerships and acquisitions. Collaborations can provide access to funding, expertise, and distribution networks, while acquisitions can add complementary technologies and products to Nxera's portfolio. The company's track record of successful collaborations, including those with AbbVie and Novartis, positions it well to capitalize on future opportunities. These partnerships can accelerate the development and commercialization of its pipeline assets.
• Geographic Expansion: Nxera Pharma currently operates in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Expanding into new geographic markets, particularly in Asia and Europe, could drive significant revenue growth. The company can leverage its existing product portfolio and development pipeline to target unmet medical needs in these regions. The emerging markets in Asia, with their rapidly growing populations and increasing healthcare spending, represent a particularly attractive growth opportunity.
• Advancement of Pipeline Assets: Nxera Pharma's development pipeline includes a range of drug candidates in various stages of clinical trials. Successful advancement of these assets through the regulatory approval process is critical to the company's long-term growth. Key pipeline assets include HTL0048149 for schizophrenia disorders and Daridorexant for the treatment of insomnia. Positive clinical trial results and regulatory approvals could lead to significant revenue generation and market share gains. The insomnia market alone is projected to reach $5 billion by 2027.
• Focus on Orphan Drug Designations: Nxera Pharma can strategically pursue orphan drug designations for its drug candidates targeting rare diseases. Orphan drug designation provides several benefits, including market exclusivity, tax credits, and reduced regulatory fees. This strategy can enhance the commercial attractiveness of Nxera's pipeline assets and provide a competitive advantage in niche markets. The company's focus on CNS disorders and inflammatory bowel disease may present opportunities to develop treatments for rare and underserved patient populations.

What Threats Does SOLTF Face?

• Regulatory hurdles and delays in drug approvals.
• Competition from larger pharmaceutical companies.
• Patent expirations and generic competition.
• Unfavorable changes in healthcare policies and reimbursement rates.

What Are SOLTF's Competitive Advantages?

• Patent protection for its proprietary drug formulations.
• Established relationships with key opinion leaders and healthcare providers.
• Strategic collaborations with major pharmaceutical companies.
• Expertise in drug development and regulatory affairs.

What Does SOLTF Do?

Nxera Pharma Co., Ltd., established in 1990 and headquartered in Tokyo, Japan, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies. The company's initial focus was on respiratory diseases, leading to the development and marketing of products like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease (COPD), as well as Enerzair and Breezhaler for asthma. Over time, Nxera has expanded its therapeutic focus to include central nervous system (CNS) disorders, metabolic diseases, and immuno-oncology. Its product portfolio also includes ORAVI for oropharyngeal candidiasis and PIVLAZ for cerebral vasospasm. Nxera's development pipeline features a range of drug candidates in various stages of clinical trials, targeting conditions such as schizophrenia, insomnia, Type 2 diabetes, obesity, and inflammatory bowel disease. The company has established strategic collaborations with major pharmaceutical companies, including AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily, to support its research and development efforts and expand its market reach. Nxera operates in Japan, Switzerland, the United States, Bermuda, and the United Kingdom.

What Products and Services Does SOLTF Offer?

• Develops and sells biopharmaceutical products.
• Focuses on treatments for respiratory diseases like COPD and asthma.
• Develops therapies for central nervous system (CNS) disorders.
• Creates treatments for metabolic diseases such as Type 2 diabetes and obesity.
• Offers products for oropharyngeal candidiasis and cerebral vasospasm.
• Engages in strategic collaborations with major pharmaceutical companies.
• Conducts research and development of new drug candidates.

How Does SOLTF Make Money?

• Develops and patents novel pharmaceutical products.
• Out-licenses or co-develops products with larger pharmaceutical companies.
• Generates revenue through sales of marketed products.
• Receives milestone payments and royalties from collaborations.

What Industry Does SOLTF Operate In?

The biotechnology industry is characterized by high growth potential and substantial risk. Companies like Nxera Pharma operate in a competitive landscape, facing challenges related to drug development, regulatory approvals, and commercialization. The market for pharmaceuticals is driven by factors such as aging populations, increasing prevalence of chronic diseases, and technological advancements. Nxera's focus on respiratory diseases, CNS disorders, and metabolic diseases aligns with key growth areas in the healthcare sector. The company's collaborations with major pharmaceutical players provide access to resources and expertise, enhancing its competitive position.

Who Are SOLTF's Key Customers?

• Patients suffering from respiratory diseases, CNS disorders, and metabolic diseases.
• Hospitals and clinics that prescribe and administer Nxera Pharma's products.
• Pharmacies that dispense Nxera Pharma's medications.
• Pharmaceutical companies through licensing and collaboration agreements.

Company Profile

Nxera Pharma Co., Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Christopher Cargill. SOLTF has traded publicly since 2013.

Return on equity for Nxera Pharma Co., Ltd. stands at -12.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.7%, the inverse of the P/E and a quick read on earnings relative to price.

SOLTF Valuation & Market Position

With a $460M market cap, Nxera Pharma Co., Ltd. sits in the small-cap segment of the market. Relative to its peer group, SOLTF's quantitative score of 58/100 is roughly in line with the peer average of 54/100.

Quarterly Financial Performance: Nxera Pharma Co., Ltd.

Revenue for Nxera Pharma Co., Ltd. came in at $7.60B during Q2 2026, a 32.9% contraction versus the preceding quarter. The company recorded a net loss of $200.5M, with diluted EPS of $-2.20. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, SOLTF averaged $-22.23 in diluted EPS.

Nxera Pharma Co., Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.94 places it in the distress zone, a signal of elevated financial risk.

Nxera Pharma Co., Ltd. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1988.2% below estimates on average.

Wall Street analysts project Nxera Pharma Co., Ltd. revenue of about $41.51B for fiscal 2026, with EPS near $46.21. The estimate reflects 7 contributing analysts.

SOLTF Financials

SOLTF Latest News

No recent news available for SOLTF.

SOLTF Analyst Consensus

SOLTF MoonshotScore

Common Questions About SOLTF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources